Currently, treatment with a novel targeted drug brentuximab vedotin (BV) [Adcetris], which is an antibody conjugate drug targeting CD30, has resulted in objective anti-tumor responses7–9. The gene discussed is TNFRSF8; the disease is neoplasm.